Ventyx Biosciences (VTYX) Receives a Buy from Oppenheimer

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $4.48.

According to TipRanks, Jones is a 5-star analyst with an average return of 29.3% and a 41.57% success rate. Jones covers the Healthcare sector, focusing on stocks such as Ventyx Biosciences, PMV Pharmaceuticals, and Perspective Therapeutics.

In addition to Oppenheimer, Ventyx Biosciences also received a Buy from Piper Sandler’s Yasmeen Rahimi in a report issued today. However, on the same day, H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (NASDAQ: VTYX).

Based on Ventyx Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $54.03 million. In comparison, last year the company had a GAAP net loss of $30.46 million

Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VTYX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ventyx Biosciences (VTYX) Company Description:

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.